NIDDK Announcement: Resources and Funding Available for Research in Nonmalignant Hematology
Dr. Terry Bishop presents a consortium of Cooperative Centers of Excellence in Hematology supported by the Division of Kidney, Urologic, and Hematologic Diseases of the Nat
And Then There Were 10: Dendritic Cells and Monocytes Undergo a Reclassification
Dr. Moss covers a radical revision of the classification of dendritic cells and monocytes.
Insightful critiques and informed commentary of important ongoing clinical trials
Dr. Keel breaks down a study that looks at the use and effects of two different doses of intravenous iron in patients with chronic kidney disease on hemodialysis.
Dr. Roberts looks at whether chemoimmunotherapy can be improved as a front-line therapy for chronic lymphocytic leukemia in fit patients.
Dr. Moss covers a study that compares the PD-1 inhibitor pembrolizumab with brentuximab vedotin in subjects with relapsed or refractory classical HL.
Dr. Garcia discusses a study that tests a new therapeutic approach with antifibrinolytic agents to chemotherapy-associated thrombocytopenia.
Dr. Cuker and Dr. George discuss a study that evaluates the safety, tolerability, and pharmacokinetics of SPK-9001 in subjects with hemophilia B.
Dr. Keel talks about a study that compares risks and benefits of alloHCT in older patients with higher-risk myelodysplastic syndromes.
Dr. Raje and Dr. Yee discuss a study that looks at the use of pembrolizumab in combination with lenalidomide or pomalidomide to treat multiple myeloma as a form of checkpoint inhibition, a new important tool in cancer treatment.
Dr. Stimpson and Dr. DeBaun look at a trial that evaluates research for HCT in severe sickle cell disease using HLA-identical siblings and unrelated donors for HCT compared with standard care due to the absence of a suitable donor.
Dr. Raetz and Dr. Loh cover a new study in pediatric ALL that tests the contribution of ruxolitinib to traditional chemotherapy for newly diagnosed, genetically defined subsets of patients who are known to have poor outcomes with standard therapy.
Dr. Coetzer discusses the N-PhenoGENICS trial and calls for new research to answer questions about secondary effects of chemotherapy in children.
July-August 2017Volume 14, Issue 4
A new Compendium providing updated clinical information to "Ask the Hematologist" articles published in The Hematologist from 2010 to 2015 is now available.